Fenwal is a leading brand in the field of blood management and transfusion technology. They develop innovative solutions to ensure the safety and availability of blood products.
1970: Fenwal was acquired by Baxter International Inc.
1983: Fenwal introduced the first automated blood collection system.
1993: Fenwal introduced the Amicus® separator, a device for blood component processing.
2007: Fenwal introduced the Alyx® component collection system, a new advancement in blood component collection.
2010: A newly spun-off Fenwal was formed and acquired by Fresenius Kabi, a global healthcare company.
Fenwal is known for its blood management and transfusion technology solutions.
Fenwal is currently owned by Fresenius Kabi, a global healthcare company.
Fenwal's main products include the Amicus® Separator, Alyx® Component Collection System, blood collection sets, and transfusion technology equipment.
Fenwal was acquired by Baxter International Inc. in 1970 and later spun off and acquired by Fresenius Kabi in 2010. They introduced innovative products like the automated blood collection system, Amicus® separator, and Alyx® component collection system.
Fenwal's main competitors include Haemonetics Corporation, Terumo BCT, B. Braun Melsungen AG, Macopharma, and Immucor.